Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

419
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
419
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

402
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
402
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

583
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
583
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

383
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
383
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

473
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
473
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

469
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
469

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zygosity and autonomic stress reactivity during social exclusion: biofeedback findings from the TwinCord-EDID study.

Frontiers in psychiatry·2026
Same author

Family matters? A Systematic review of interventions addressing family-level mechanisms in the treatment of childhood and adolescent obesity.

Reviews in endocrine & metabolic disorders·2026
Same author

Prenatal and postnatal maternal obesity and their associations with child nutrition and weight outcomes: A systematic review.

Reviews in endocrine & metabolic disorders·2026
Same author

Changes in olfactory function in children and adolescents with obesity following an inpatient weight loss program: a longitudinal study.

BMC medicine·2026
Same author

Drug Delivery Strategy Exploiting Amino Acid Prodrugs: Improving Oral Bioavailability and Overcoming Nonlinear Pharmacokinetic Challenges Following Dose Escalation of a CK2 Inhibitor with Poor Solubility.

Journal of medicinal chemistry·2026
Same author

The cross-sectional and prospective associations between time-restricted eating and cardiometabolic health in community-dwelling adults: A systematic review and meta-analysis of observational studies.

European journal of clinical nutrition·2026

Related Experiment Video

Updated: Oct 30, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

973

A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

Isabelle Mack1, Juliane Schwille-Kiuntke2, Nazar Mazurak1

  • 1Department of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Tübingen.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|July 2, 2021
PubMed
Summary

This study found that a nonviable probiotic lysate (BL) was not effective for irritable bowel syndrome (IBS) overall. However, BL showed potential benefits for diarrhea-predominant IBS (IBS-D) symptom relief, warranting further investigation.

Keywords:
Abdominal PainDiarrheaIrritable Bowel SyndromeParaprobiotics

More Related Videos

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

9.9K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.5K

Related Experiment Videos

Last Updated: Oct 30, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

973
An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

9.9K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.5K

Area of Science:

  • Gastroenterology
  • Microbiome research
  • Clinical trial methodology

Background:

  • Irritable bowel syndrome (IBS) is a common gastrointestinal disorder.
  • Current treatments offer limited efficacy for many patients.
  • Exploring novel therapeutic agents like probiotic lysates is crucial.

Purpose of the Study:

  • To evaluate the efficacy of a nonviable probiotic lysate (BL) derived from Escherichia coli and Enterococcus faecalis in patients with IBS.
  • To assess the impact of BL on global IBS symptoms and abdominal pain.

Main Methods:

  • A Phase IV, randomized, double-blind, placebo-controlled, multicenter study.
  • 389 patients diagnosed with IBS according to Rome III criteria participated.
  • Treatment involved 26 weeks of oral BL or placebo, with primary outcomes being global assessment and abdominal pain improvement.

Main Results:

  • No significant difference was observed between BL and placebo for the overall IBS global assessment or abdominal pain.
  • Some secondary analyses suggested potential benefits of BL for abdominal pain in diarrhea-predominant IBS (IBS-D).
  • The treatment was well-tolerated with no significant adverse events reported.

Conclusions:

  • The nonviable probiotic lysate (BL) demonstrated no overall effectiveness across all IBS subtypes.
  • BL may represent a potential therapeutic option for IBS-D, requiring confirmation in larger, powered trials.
  • Further research is needed to validate these preliminary findings for IBS-D.